MDT: Leadership change · Company disclosure

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 15, 2026, the Board of Directors (the "Board") of Medtronic plc (the “Company”) approved the appointment of Michael Marinaro, Executive Vice President and President, Medical Surgical Portfolio, Americas, and Global Commercial Operations to the role of President, Medtronic, effective October 14, 2026. In this expanded role, Mr. Marinaro will continue with his current responsibilities, in addition to exercising oversight responsibility for the Company’s Greater China operations, which will continue to be managed locally by Alex Gu, Senior Vice President and President, Greater China. Mr. Marinaro will continue to report to Geoffrey S. Martha, who will continue to serve as the Company’s Chairman of the Board of Directors and Chief Executive Officer. In connection with Mr. Marinaro’s appointment as President, Medtronic, the Compensation and Talent Committee (the "Committee") of the Board approved changes to his compensation, including an increase in Mr. Marinaro's annual base salary to $1,000,000 for all of fiscal year 2027. Mr. Marinaro's target annual incentive opportunity under the Medtronic Incentive Plan will continue to equal 100% of his annual base salary. In addition, the Committee approved supplemental fiscal year 2027 long-term incentive awards with an aggregate target value of approximately $3.25 million, consisting of (i) a performance share unit award with a target value of $1.625 million, (ii) a stock option award with a grant date value of $975,000 and (iii) a restricted stock unit award with a value of $650,000, each to be granted on November 2, 2026 pursuant to the Company’s 2021 Medtronic plc